摘要

背景:生长抑素类似物可有效控制类癌综合征患者的潮红和腹泻。八肽lanreotide以缓释形式提供，这可以消除像奥曲肽那样每天两次注射的必要性。患者和方法:39例类癌综合征患者被纳入一项前瞻性多中心研究。患者每14天肌肉注射lanreotide 30 mg，持续6个月。记录了潮红发作和排便的次数和强度、尿中5羟基吲哚乙酸(5 HIAA)浓度以及肿瘤体积的变化。结果:治疗一个月后，潮红发作(中位数(范围))显著减少(每天3(0.3-24)次v 1(0-15)次，p = 0.04)， 39%的患者完全缓解。排便次数和腹泻引起的不适明显减少。57%的患者尿中HIAA浓度没有变化，18%的患者尿中HIAA浓度下降。经过6个月的治疗后，潮红发作次数和排便次数减少至少50%的患者精算比例分别为54%和56%。在接受了6个月治疗的患者中，42%的患者HIAA值至少降低了50%。 No clear signs of regression of tumours were seen in any of the patients. Lanreotide was well tolerated despite transient mild pain or erythema at the injection site in 25% of the patients. Biliary lithiasis appeared in two patients after six months of lanreotide. CONCLUSION: Lanreotide, 30 mg intramuscularly every other week, is an effective and convenient treatment in patients with the carcinoid syndrome.